Biogen Inc. (ETR:IDP)
Germany flag Germany · Delayed Price · Currency is EUR
126.95
-1.40 (-1.09%)
Mar 31, 2025, 1:25 PM CET

Biogen Company Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA.

It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.

In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars.

Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome.

The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc.
Biogen logo
Country United States
Founded 1978
Industry Drug Manufacturers - General
Sector Healthcare
Employees 7,605
CEO Christopher Viehbacher

Contact Details

Address:
225 Binney Street
Cambridge, Delaware 02142
United States
Phone (617) 679-2000
Website biogen.com

Stock Details

Ticker Symbol IDP
Exchange Deutsche Börse Xetra
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
ISIN Number US09062X1037
SIC Code 2836

Key Executives

Name Position
Christopher A. Viehbacher President, Chief Executive Officer and Director
Nicole Murphy Executive Vice President and Head of Pharmaceutical Operations and Technology
Susan H. Alexander Esq. Executive Vice President and Chief Legal Officer
Rachid Izzar Executive Vice President and Head of Global Product Strategy and Commercialization
Robin C. Kramer Executive Vice President and Chief Financial Officer
Sean Godbout Chief Accounting Officer and Global Corporate Controller
Tim Power M.B.A., Ph.D. Head of Investor Relations
Natacha Gassenbach Chief Communication Officer and Head of Corporate Affairs
Adam Keeney Ph.D. Executive Vice President and Head of Corporate Development
Dr. Ginger Gregory Ph.D. Executive Vice President and Chief Human Resources Officer